APGE logo

APOGEE THERAPEUTICS INC

APGENASDAQ
🏆 #808 by market capEarnings Nov 9US Equity
$135.08▲ $0.00 (+0.00%)
Market closed · at close
🔔
Track APGE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.0%
7d—
14d—
30d—
ytd▲ 78.9%
1y▲ 142.5%
🏦Market Cap
$10.22B
Mid Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$135.06 – $135.09
52-Week Range
$51.80 – $135.09
Volume (shares)
85,895
Avg Volume (shares)
—
Shares Outstanding
75.7M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-4.34
Dividend Yield
—
Dilution (1yr)
+10.0%
APGE logo

APOGEE THERAPEUTICS INC

APGE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$286M▲ +31.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$233M▲ +35.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
60.7M▲ +10.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$123M▼ −$7M YoY
StockOtter · stockotter.space

About APOGEE THERAPEUTICS INC

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Hold
21 analysts
Strong Buy2
Buy4
Hold15
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.